Adatanserin

This classification denotes a serotonin antagonist with the molecular formula C21H31N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5U6WQM26H, chemically known as tricyclo(3.3.1.1(3,7))decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)- but generally known as adatanserin, which bears US NIH Compound Identifier 130918. Adatanserin comes in base and hydrochloride form. European Medicines Agency schedules Adatanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05263MIG. The term ADATANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). ADATANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adatanserin under HS 29335995 and SITC 51576. As of Q4 2014, ADATANSERIN remains the US FDA Preferred Term for this commodity. Adatanserin bears US NLM identifiers UMLS ID C0216334 and NCI Concept Code C75981. SMILES: O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(C1)CC(C2)C3.